Patents by Inventor Kenneth Verstraete

Kenneth Verstraete has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GALECTIN-10 ANTIBODIES
    Publication number: 20240026010
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Application
    Filed: June 7, 2023
    Publication date: January 25, 2024
    Inventors: Jean-Michel PERCIER, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • Galectin-10 antibodies
    Patent number: 11713354
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: August 1, 2023
    Assignees: ARGENX BV, VIB VZW, Universiteit Gent
    Inventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • GALECTIN-10 ANTIBODIES
    Publication number: 20210332140
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Application
    Filed: March 8, 2021
    Publication date: October 28, 2021
    Inventors: Jean-Michel PERCIER, Christophe BLANCHETOT, Michael SAUNDERS, Hans DE HAARD, Sebastian VAN DER WONING, Emma PERSSON, Bart LAMBRECHT, Savvas SAVVIDES, Hamida HAMMAD, Kenneth VERSTRAETE
  • Galectin-10 antibodies
    Patent number: 11066473
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: July 20, 2021
    Assignees: argenx IIP BV, VIB VZW, Universiteit Gent
    Inventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete
  • TSLP inhibitors
    Patent number: 11001624
    Abstract: The present invention relates to monomeric fusion proteins comprising the extracellular part of the thymic stromal lymphopoietin receptor (TSLPR) and the extracellular part of the interleukin-7 receptor alpha (IL-7Ralpha) as inhibitors of thymic stromal lymphopoietin (TSLP) activity. The invention relates further to the use of said inhibitors as a medicament in the treatment of—but not limited to—inflammatory diseases, cancer and fibrosis.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: May 11, 2021
    Assignees: VIB VZW, UniversiteitGent
    Inventors: Savvas Savvides, Rudi Beyaert, Kenneth Verstraete, Harald Braun, Frank Peelman
  • GALECTIN-10 ANTIBODIES
    Publication number: 20190367619
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Application
    Filed: April 12, 2019
    Publication date: December 5, 2019
    Inventors: Jean-Michel PERCIER, Christophe BLANCHETOT, Michael SAUNDERS, Hans DE HAARD, Sebastian VAN DER WONING, Emma PERSSON, Bart LAMBRECHT, Savvas SAVVIDES, Hamida HAMMAD, Kenneth VERSTRAETE
  • NOVEL TSLP INHIBITORS
    Publication number: 20190127440
    Abstract: The present invention relates to monomeric fusion proteins comprising the extracellular part of the thymic stromal lymphopoietin receptor (TSLPR) and the extracellular part of the interleukin-7 receptor alpha (IL-7Ralpha) as inhibitors of thymic stromal lymphopoietin (TSLP) activity. The invention relates further to the use of said inhibitors as a medicament in the treatment of—but not limited to—inflammatory diseases, cancer and fibrosis.
    Type: Application
    Filed: April 4, 2017
    Publication date: May 2, 2019
    Inventors: Savvas Savvides, Rudi Beyaert, Kenneth Verstraete, Harald Braun, Frank Peelman
  • CRYSTAL STRUCTURE OF FLT3 LIGAND-RECEPTOR COMPLEX
    Publication number: 20130288373
    Abstract: The present invention relates to the crystal structure of Flt3 and its cognate ligand FL. In particular, the binding interface of Flt3 and its cognate ligand FL has been determined. The present invention also relates to the applicability in modulating Flt3 activity. Methods for the identification as well as the rational design of mediators of Flt3 signaling are disclosed. In an aspect the method comprises a step of employing the atomic coordinates representing the three-dimensional structure of Flt3 and/or FL.
    Type: Application
    Filed: December 20, 2011
    Publication date: October 31, 2013
    Inventors: Kenneth Verstraete, Savvas Savvides